Efficacy and Safety of Low-Dose Isotretinoin in the Treatment of Acne Vulgaris: A Prospective study
DOI:
https://doi.org/10.32007/jfacmedbaghdad3275Keywords:
Acne vulgaris, cumulative dose, isotretinoin, low-dose therapy, relapseAbstract
Background: Conventional isotretinoin dosing (0.5–1.0 mg/kg/day) for acne vulgaris achieves high efficacy, but is limited by significant adverse effects. Low-dose regimens (≤ 0.5 mg/kg/day) may offer an improved therapeutic ratio.
Objectives: To evaluate the efficacy, safety, and relapse outcomes of a flexible low-dose isotretinoin protocol in Iraqi adolescents and young adults.
Methods: A prospective single-arm study involving 72 patients aged 14–25 years) with mild-to-severe acne vulgaris received isotretinoin 0.1–0.5 mg/kg/day for 16–20 weeks. The study was conducted at the Dermatology Outpatient Clinic of Al-Diwaniyah Teaching Hospital, Iraq, between January 2023 and December 2024. The clinical response was assessed using the Investigator's Global Assessment. Safety was monitored via adverse events and laboratory tests for liver function and lipid profile. The patients were followed for 6–12 months for relapse assessment. Data were analyzed using the SPSS software and presented using descriptive statistics.
Results: Treatment success was achieved in 88.9% (64/72) of the patients. Adverse events were mild including cheilitis (97.2%), xerosis (4.2%), myalgia (2.8%), dry eyes (4.2%), and transient headache (2.8%). No mood alterations or severe skin reactions occurred. No significant laboratory abnormalities were noted. During follow-up, 27.8% (20/72) relapsed; all successfully completed a second identical low-dose course.
Conclusion: Low-dose isotretinoin demonstrates high efficacy and safety. Even as relapse rates are higher than with conventional dosing, the good tolerability supports its use as a first-line strategy, with re-treatment being a viable option.
Received: 27 Jan. 2026,
Revised:3 May 2026,
Accepted:17 May 2026,
Published Online: June 2026
References
. Etgü F, Tatar GS. Risk Factors and Epidemiology of Acne Severity and Acne Scar Development: A Comprehensive Clinical Study. Dermatol Pract Concept. 2025;15(4):6108. https://doi.org/10.5826/dpc.1504a6108
2. Ahmadi NA. Psychosocial Impact of Acne in Adolescents: Prevalence, Contributing Factors, and Management Approaches. Salamat ARJ. 2024;1(1):47-52. https://doi.org/10.61438/sarj.v1i1.81
3. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am AcadDermatol. 2016;74(5):945-973.e33. https://doi.org/10.1016/j.jaad.2015.12.037
4. Chen YH, Wang WM, Chung CH, et al. Risk of psychiatric disorders in patients taking isotretinoin: a nationwide, population-based, cohort study in Taiwan. J Affect Disord. 2022;296:277-282. https://doi.org/10.1016/j.jad.2021.09.055
5. Droitcourt C, Poizeau F, Kerbrat S, et al. Isotretinoin and risk factors for suicide attempt: a population-based comprehensive case series and nested case-control study using 2010-2014 French Health Insurance Data. J Eur Acad Dermatol Venereol. 2020;34(6):1293-1301. https://doi.org/10.1111/jdv.16005
6. Kruglova LS, Gryazeva NV, Sidorenko EV. Isotretinoin for moderate to severe acne: current recommendations. Med Alf. 2021;(27):20-25. https://doi.org/10.33667/2078-5631-2021-27-20-25
7. İslamoğlu ZG, Altınyazar HC. Effects of isotretinoin on the hair cycle. J Cosmet Dermatol. 2019;18(2):647-651. https://doi.org/10.1111/jocd.12800
8. Alajaji A, Alrawaf FA, Alosayli SA, et al. Laboratory Abnormalities in Acne Patients Treated With Oral Isotretinoin: A Retrospective Epidemiological Study. Cureus. 2021;13(10):e19031. https://doi.org/10.7759/cureus.19031
9. Sarkar T, Sarkar S, Patra A. Low-dose isotretinoin therapy and blood lipid abnormality: A case series with sixty patients. J Family Med Prim Care. 2018;7(1):171-174. https://doi.org/10.4103/jfmpc.jfmpc_104_16
10. Anaam MS, AlShibl DA, Alfadly S, et al. Adverse Effects and Precautionary Measures for Isotretinoin Use in Patients with AcneVulgaris: A Single-Center Study. Healthcare. 2025;13(13):1617.
https://doi.org/10.3390/healthcare13131617
11. Van TLT, Minh PN, Thuy PT, et al. Efficacy of Oral Low-Dose Isotretinoin in the Treatment of AcneVulgaris in Vietnam. Open Access Maced J Med Sci. 2019;7(2):279-282. https://doi.org/10.3889/oamjms.2019.094
12. Ding RL, Zheng Y, Bu J. Physiological and Psychological Effects of Isotretinoin in the Treatment of Patients with Acne: A Narrative Review. Clin Cosmet Investig Dermatol. 2023;16:1843-1854.
https://doi.org/10.2147/CCID.S416267
13. Costa CS, Bagatin E, Martimbianco ALC, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev. 2018;11:CD009435. https://doi.org/10.1002/14651858.CD009435.pub2
14. Daly AU, Baptista Conçalves R, Lau E, et al. A systematic review of isotretinoin dosing in acne vulgaris. J Eur Acad Dermatol Venereol Clin Pract . 2023;2:432-449. https://doi.org/10.1002/jvc2.154
15. Sadeghzadeh-Bazargan A, Ghassemi M, Goodarzi A, et al. Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies. Dermatol Ther. 2021;34(1):e14438. https://doi.org/10.1111/dth.14438
16. Dhaked DR, Meena RS, Maheshwari A, et al. A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris. Indian Dermatol Online J. 2016;7(5):378-385. https://doi.org/10.4103/2229-5178.190505
17. Al Muqarrab F, Almohssen A. Low-dose oral isotretinoin for the treatment of adult patients with mild-to-moderate acne vulgaris: Systematic review and meta-analysis. Dermatol Ther. 2022;35(4):e15311.
https://doi.org/10.1111/dth.15311
18. Legiawati L, Fahira A, Taufiqqurrachman I, et al. Low-Dose versus Conventional-dose Oral Isotretinoin Regimens: A Systematic Review on Randomized Controlled Comparative Studies of Different Regimens. Curr Drug Saf. 2023;18(3):297-306. https://doi.org/10.2174/1574886317666220613162225
19. Hafeez L, Khan AN, Aslam A, et al. Comparison of safety and efficacy of low dose isotretinoin versus the conventiona ldosing regime in the treatment of acne vulgaris. J Pak Assoc Dermatol. 2020;30(3):423-427. https://doi.org/10.66344/jpad.30.3.2020.1484
20. Li Y, Zeng Y, Chen Z, et al. The efficiency and safety of low-dosage isotretinoin therapy for Chinese acne vulgaris patients. J Cosmet Dermatol. 2024;23(3):926-930. https://doi.org/10.1111/jocd.16073
21. Lin L, Lin W, Zheng Y, et al. Effectiveness and safety of different dosing regimens of isotretinoin for acne vulgaris: a systematic review. Postepy Dermatol Alergol. 2025;42(4):346-353. https://doi.org/10.5114/ada.2025.153322
22. Tan J, Boyal S, Desai K, et al. Oral isotretinoin: new developments relevant to clinical practice. Dermatol Clin. 2016;34(2):175-184.
https://doi.org/10.1016/j.det.2015.11.002
23. Bagatin E, Costa CS. The use of isotretinoin for acne - an update on optimal dosing, surveillance, and adverse effects. Expert Rev Clin Pharmacol. 2020;13(8):885-897. https://doi.org/10.1080/17512433.2020.1796637
24. Al-Chalabi K, Fathi H, Al-Mallah M. CAN LOW DOSE OF ISOTRETINOIN CAUSE DEPRESSION. Mosul Journal of Nursing, 2020; 8(1):60-67. Available from: https://mjn.uomosul.edu.iq/article_164621.html
25. Paichitrojjana A, Paichitrojjana H. Oral Isotretinoin and Its Uses in Dermatology: A Review. Drug Des DevelTher. 2023;17:2573-2591.
https://doi.org/10.2147/DDDT.S427530
26. Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178(1):76-85. https://doi.org/10.1111/bjd.15668
27. Shetti SA, Nagesh HN, Hanumantharaya N. A randomized, open-label, comparative study of efficacy of low-dosecontinuous versus low-dose intermittent oral isotretinoin therapy in moderate-to-severe acne vulgaris. Natl J Physiol Pharm Pharmacol. 2017;7(9):941-946.
https://doi.org/10.5455/njppp.2017.7.0305804052017
28. Feszak IJ, Brzeziński P, Feszak S, et al. Isotretinoin Treatment for AcneVulgaris: A Five-Year Retrospective Analysis of Clinical and Biochemical Adverse Effects. J Clin Med. 2025;14(18):6473. https://doi.org/10.3390/jcm14186473
29. MacGibeny MA, Jo JH, Kong HH. Antibiotic Stewardship in Dermatology-Reducing the Risk of Prolonged Antimicrobial Resistance in Skin. JAMA Dermatol. 2022;158(9):989-991. https://doi.org/10.1001/jamadermatol.2022.3168
Creative Commons Attribution 4.0 International license..
